A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Deborah Christie
Professor of Paediatric and Adolescent Psychology, University College London Hospitals and Dartford and Gravesham NHS Trusts
Citation: Christie D (2023) Q&A: Breaking the cycle – Empowering healthcare professionals to overcome stigma in diabetes care. Diabetes & Primary Care 25: 183–6 Q&A
Article disclosure: This article describes research commissioned by Abbott, and Professor Christie was paid a fee by Abbott to contribute to this article. The views expressed are those of the author and not necessarily those of Abbott. The article was commissioned by the Editorial Board as a topic of interest. The journal has received no funding, and all peer review and editorial decisions have been made independently and according to the journal’s usual procedures.
Citation: Christie D (2023) Q&A: Breaking the cycle – Empowering healthcare professionals to overcome stigma in diabetes care. Diabetes & Primary Care 25: 183–6
Background: Chronic wounds fail to progress through a normal sequence of repair. This study aimed to evaluate the chronic wound patient journey among healthcare professionals (HCPs) and patients in Indian settings.
Methods: A survey questionnaire was framed, including patient burden, initial diagnosis and treatment preference, referral pathway, challenges, and unmet needs of HCPs and patients.
Results: A total of 100 HCPs and 30 patients participated in the survey. The primary challenges faced by the patients include high treatment costs and accessibility to healthcare centres while HCPs reported high treatment cost and lack of awareness as challenges. Affordable treatment options and lack of awareness were cited as prime unmet needs by both HCPs and patients.
Conclusion: The use of adapted products and early initiation of treatment can aid in faster wound healing and can be cost-effective.
Authors:
Arun Bal, Sanjay Vaidya, Rajiv Parakh, Vivekanand, Pavan Belehalli, Madhu Periasamy, Jessy Thomas, Bharat Kotru, Beulah Priyadharshini D R, Venugopal K and Pratik Bhide
Arun Bal is Consultant Diabetic Foot Surgeon, S L Raheja Hospital, Mumbai, India;
Sanjay Vaidya is Consultant Plastic Surgeon, S L Raheja Hospital, Mumbai, India;
Rajiv Parakh is Consultant– Peripheral Vascular and Endovascular Surgery, Medanta Hospital, Gurugram, India;
Vivekanand is Consultant Vascular Surgeon, BMJ Hospital, Bangalore, India;
Pavan Belehalli is Orthopaedic Surgeon, KIER, Bangalore, India;
Madhu Periasamy is Consultant Plastic Surgeon, Ganga Hospital, Coimbatore, India;
Jessy Thomas is Surgeon – Podiatry, Hiranandani Hospital, Mumbai, India;
Bharat Kotru is Podiatrist and Wound Care Specialist, Max Hospital and Amandeep Hospital, Amritsar, India;
Beulah Priyadharshini D R is Medical Affairs Manager – India, Urgo Medical;
Venugopal K is Medical Affairs & Training Specialist – India, Urgo Medical;
Pratik Bhide is Managing Director, India, Urgo Medical
Providencia rettgeri is a Gram-negative bacillus that is most usually seen in urinary tract infections. Skin and soft tissue infections with P rettgeri are rare and there few case reports described in the literature. A 43-year old woman presented to the emergency department with a leg ulcer of 3 months duration. Microbiological results isolated P rettgeri and Pseudomonas aeruginosa. She underwent surgical debridement and split-thickness skin grafting alongside IV antibiotic therapy and dressing care, with complete resolution of the wound 3 months after admission. The differential diagnosis of leg ulcers is wide and must include infection and venous insufficiency. Although venous ulcers are common, typically they are not responsible for rapid evolving ulcers that destroy tissues below the muscular fascia. In this case report, the authors hypothesise that P rettgeri had a major role in the severity of the ulcer in an otherwise healthy woman. A greater understanding of how P rettgeri affects wound pathophysiology is needed in order to distinguish between colonisation versus infection and discriminate bacterial synergy, as well as having better treatment guidelines.
Miguel Veríssimo, Diogo Guimarães, Diogo Casal, Sara Carvalho, Miguel Matias, Raquel Barbosa and Joaquim Bexiga
Miguel Veríssimo is Resident. Diogo Guimarães is Resident. Diogo Casal is Attending Physician. Sara Carvalho is Attending Physician. Miguel Matias is Resident. Raquel Barbosa is Resident. Joaquim Bexiga is Attending Physician. All at Plastic Surgery Department, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.
What makes a good formulary?
The importance of evidencebased practice
Considering cost
Change management
Addressing challenges and
measuring success
BEST PRACTICE STATEMENT: DEVELOPMENT OF A WOUND CARE FORMULARY USING CLINICAL EVIDENCE AND ENSURING EFFECTIVE CHANGE MANAGEMENT
PUBLISHED BY:
Wounds UK
A division of Omniamed Communications, 108 Cannon Street London EC4N 6EU, UK www.wounds-uk.com
This document has been developed by Wounds UK and is supported by an unrestricted educational grant from Urgo Medical.
This publication was coordinated by Wounds UK with the Expert Working Group and Review Panel. The views presented in this document are the work of the authors and do not necessarily
How to cite this document:
Wounds UK (2023) Best Practice Statement: Development of a wound care formulary using clinical evidence and ensuring effective change management. Wounds UK, London. Available to download from: www.woundsuk.com reflect the views of Urgo Medical.
EXPERT WORKING GROUP:
Jacqui Fletcher OBE (Chair), Independent Nurse Consultant
Andrew Sharpe, Advanced Podiatrist, Wound Care, Salford Care Organisation, Salford
Caroline Dowsett, Clinical Nurse Specialist, Tissue Viability Services, East London NHS Foundation Trust
David Wylie, Managing Director, DAWN Health & Care Consultancy UK Ltd; Honorary Fellow, Glasgow Caledonian University, Glasgow
Dawn Douglas, Community Matron, Northumbria Healthcare NHS Foundation Trust
Graham Bowen, Principal Podiatrist, Solent NHS Trust
Hollie Robinson, Tissue Viability Service Lead, South Warwickshire NHS Foundation Trust
Joy Tickle, Tissue Viability Nurse Consultant, Isle of Wight NHS Trust
Kelly Phillips, Skin Integrity Lead Nurse, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
Leanne Atkin, Vascular Nurse Consultant, Mid Yorkshire NHS Trust; Research Fellow, University of Huddersfield
Michelle Goodeve, Senior Diabetes Specialist Podiatrist, Provide Community Interest Company
Nina Murphy, Operational Lead for Tissue Viability, North East London NHS Foundation Trust
Rebecca Elwell, Trustee, British Lymphology Society; Macmillan Lymphoedema ANP and Team Leader, University Hospitals of North Midlands NHS Trust
Sian Fumarola, Head of Clinical Procurement, North Midlands and Black Country NHS Procurement Group
Jane Diggle
Specialist Diabetes Nurse
Practitioner, West Yorkshire
Citation: Diggle J (2023) Updates in the management of cardiovascular disease. Diabetes & Primary Care 25: 145–7
Background: Ideally, a good skin graft substitute should be readily available, cost-effective, have a low disease transmission risk, reduce infection and scarring, and aid wound healing. Fish skin grafts (FSG) are an accessible option to most populations.
Aim: This literature review explores the use of FSG, as a xenograft, to aid in wound healing and the potential benefits or harms of using this intervention.
Methods: A literature search using the PICO method was conducted on MEDLINE, CINAHL Plus, Cochrane Library, Web of Science and Embase, and hand searched on the Cardiff University Library.
Results: FSG aided faster healing of burn wounds and reduced scarring. However, there was a lack of studies that examined the patient’s experience and the long-term effects of FSG.
Conclusions: FSG has multiple biological, economical and logistical benefits. It should be considered as an alternative graft option and has been shown to be useful in low resource environments. However, more robust research on the harms and benefits of FSG use is required.
KEY WORDS
Burns
Fish skin graft
Skin graft
Traumatic wounds
Wound healing
VENNESSA C. LEE BN, RN Tissue Viability Nurse, HCA UK
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。